West China Hospital, Sichuan University has described heteroatom-substituted aromatic compounds reported to be useful for the treatment of pain and as general anesthetics.
Sunshine Lake Pharma Co. Ltd. has divulged benzazepine heterocyclic compounds acting as nuclear receptor RORγT (T cell-specific isoform 2) agonists reported to be useful for the treatment of cancer, rheumatoid arthritis, psoriasis, asthma, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and Kawasaki disease, among others.
Shanghai Allist Pharmaceuticals Co. Ltd. has synthesized nitrogen-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) and (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
Immpact Bio USA Inc. has announced clearance of its IND application by the FDA for IMPT-314, a bispecific OR-Gate autologous chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell antigens CD19 and CD20.
The FDA has cleared Cullinan Oncology Inc.'s IND application for CLN-978, a CD19/CD3 T-cell engaging antibody construct with a human serum albumin (HSA) binding domain to increase serum half-life.
Outcomes after therapy with DNA-damaging agents such as irinotecan or oxaliplatin have been seen to improve in patients with homologous recombination-deficient colorectal cancer (HRD CRC) compared to those who have HR proficient CRC (HRP CRC).
RSS
